Filing Flows › Stereotaxis (STXS) › Recalls, complaints & regulation
Stereotaxis (STXS): clinical trials
Stereotaxis (STXS) beyond its filings: 2 active clinical trials.
Stereotaxis' latest quarter
Stereotaxis, Q2 2026: revenue $7.7M (-13% year over year), operating margin -59.6%, net loss $4.5M, operating cash flow −$3.7M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Stereotaxis have?
2 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.